Peter R. Dolan

Peter R. Dolan is an American business executive best known for his tenure as the chief executive officer of the global pharmaceutical company Bristol-Myers Squibb. His career at the firm was marked by significant strategic initiatives but ultimately ended amid controversy. Following his departure, Dolan rebuilt his career through advisory roles and corporate board directorships, establishing himself as a seasoned leader in the healthcare and private equity sectors.

Early life and education

Peter R. Dolan was born in 1956. He pursued his undergraduate education at Tufts University, graduating with a degree in economics. He then attended the Amos Tuck School of Business Administration at Dartmouth College, where he earned his Master of Business Administration. His academic foundation in economics and advanced business management prepared him for a career in the complex landscape of corporate strategy and finance.

Career at Bristol-Myers Squibb

Dolan joined Bristol-Myers Squibb in 1988, ascending through various marketing and management positions. He was appointed president and chief operating officer in 2000 before becoming the company's chief executive officer in 2001, also assuming the role of chairman of the board. His leadership focused on navigating challenges such as patent expirations for key drugs like Plavix and fostering pipeline development through partnerships, including a notable collaboration with ImClone Systems for the cancer drug Erbitux. However, his tenure was significantly impacted by a federal investigation into the company's actions to delay generic competition for Plavix. This led to a deferred prosecution agreement with the U.S. Department of Justice and ultimately to his dismissal by the Bristol-Myers Squibb board of directors in 2006.

Post-Bristol-Myers Squibb career

After leaving Bristol-Myers Squibb, Dolan became a senior advisor to the private equity firm Gotham Capital and its founder Joel Greenblatt. He later served as a partner at the healthcare investment firm Caxton Advantage Life Sciences Fund. In these roles, he applied his extensive pharmaceutical industry experience to investment strategy and portfolio company guidance. He also served as the chief executive officer of Gemini Therapeutics, a clinical-stage biopharmaceutical company, steering its early development efforts before stepping down from that role.

Other roles and board memberships

Dolan has held numerous corporate board positions, contributing governance expertise across industries. He has served as a director for Covidien, the medical device giant later acquired by Medtronic, and for the biotechnology firm Ariad Pharmaceuticals. His board service extended to The Dun & Bradstreet Corporation, Nortek, Inc., and Valeant Pharmaceuticals International. Within the nonprofit sector, he has been a trustee of Tufts University and chairman of the board for the National Pharmaceutical Council, engaging with issues at the intersection of healthcare policy and business.

Personal life

Dolan maintains a connection to his alma mater, Tufts University, through his philanthropic and advisory activities. He is married and has children. Details regarding his family life and residence are kept private, consistent with his focus on professional endeavors in the realms of corporate governance, private equity, and healthcare investment.

Category:American business executives Category:1956 births Category:Tufts University alumni Category:Dartmouth College alumni